Perioperative Considerations for Anticoagulation With Mechanical Dev…

James Douketis

Managing Complications of Dermatologic Surgery

Masterclasses in Dermatology

D. Siegel

Five Things Every Internist Should Know About Anticoagulants

McMaster University Department of Medicine

S. Mithoowani

Mechanical Microvascular Protection is Not Needed with the Right Pha…

Tim Fischell

Antithrombotic Pharmacology in ACS PCI: What’s Practical, What’s in …

Scottsdale Interventional Forum 2013

R. Harrington

Management of AF patients with ACS

Lankenau

P. Kowey, D. Ice

Essentials of ACS/PCI Pharmacology: An Overview and Approach

Scottsdale Interventional Forum 2014

R. Harrington

Friday Lunch - Conversations in Cardiology Featuring Morton J Kern

Scottsdale Interventional Forum 2014

M. Kern

Anticoagulation After LAA Closure

Congenital and Structural Interventions

M. Bergmann

PCI Pharmacology in 2015: Choosing the Right Antiplatelet & Anticoag…

Scottsdale Interventional Forum 2015

S. Bailey

Beyond ISAR Triple: Optimal Triple Drug Therapy After DES Implantati…

Scottsdale Interventional Forum 2015

M. Kutcher

Update on PCI Pharmacology: What the Interventionalist needs to know…

Scottsdale Interventional Forum 2016

S. Bailey

What is the Role of Left Atrial Appendage Therapies in Comparison to…

Scottsdale Interventional Forum 2016

Acute Coronary Syndrome Update

ARCH Advanced Revascularization Symposium

R. Bach

Bivalirudin, IIB/IIA Inhibitors, UFH and DAPT Cocktails For STEMI

Emory Practical Intervention Course – Southeastern Consortium (EPIC-SEC) 2015

D. Angiolillo

Is Coumadin Dead? Are Novel Anticoagulant Drugs the Optimal Therapy?…

Cardiology Fiesta 2016

B. Kalich

Bivalirudin vs. Heparin

ARCH Advanced Revascularization Symposium

A. Amin

Bivalirudin vs. Heparin

ARCH Advanced Revascularization Symposium

D. Cox

New Antiplatelet Agents

Complex Coronary Valvular and Vascular Cases Conference

DAPT Durations – How Long is Enough?

Northwell Health Cardiovascular Fellows Course 2018

C. Grines